{"id":"pegifn-alfa-2a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression"},{"rate":"10-15","effect":"Injection site reactions"},{"rate":"10-15","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylation extends the half-life of interferon alfa-2a by conjugating polyethylene glycol to the protein, allowing less frequent dosing. The drug binds to type I interferon receptors on immune cells, enhancing antiviral and antiproliferative activities. It stimulates natural killer cells, macrophages, and cytotoxic T lymphocytes to combat viral infections and abnormal cell growth.","oneSentence":"PegIFN alfa-2a is a pegylated interferon alpha-2a that activates innate immune responses by binding to interferon-alpha receptors on immune cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:46.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT02594293","phase":"PHASE4","title":"Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-10","conditions":"Chronic Hepatitis B","enrollment":180},{"nctId":"NCT03575208","phase":"PHASE2","title":"Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2019-02-13","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT02908191","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":86},{"nctId":"NCT02745704","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-04","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02838810","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-06","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT03020004","phase":"PHASE2","title":"Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-01","conditions":"Chronic Hepatitis C","enrollment":70},{"nctId":"NCT03109730","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2017-06-15","conditions":"Chronic Hepatitis B","enrollment":38},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT00932971","phase":"PHASE2","title":"HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2009-06","conditions":"Hepatitis D","enrollment":70},{"nctId":"NCT01265511","phase":"PHASE2","title":"Study of SCY-635, Pegasys and Copegus in Hepatitis C","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2010-11","conditions":"Hepatitis C Infection","enrollment":10},{"nctId":"NCT01567735","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-03-27","conditions":"Hepatitis C","enrollment":107},{"nctId":"NCT00204529","phase":"PHASE3","title":"Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2004-10","conditions":"Melanoma","enrollment":901},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT00537407","phase":"PHASE2","title":"A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2007-09","conditions":"Chronic Hepatitis C","enrollment":50},{"nctId":"NCT01724086","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":90},{"nctId":"NCT02644538","phase":"PHASE4","title":"Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2015-12","conditions":"Hepatitis B","enrollment":196},{"nctId":"NCT02589652","phase":"","title":"Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2015-10","conditions":"Chronic Hepatitis B","enrollment":294},{"nctId":"NCT01204762","phase":"PHASE2","title":"Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-11","conditions":"Hepatitis B Virus","enrollment":197},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT00947349","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-07","conditions":"Hepatitis C, Pharmacokinetics","enrollment":22},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT00877760","phase":"PHASE4","title":"Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2009-08","conditions":"Chronic Hepatitis B","enrollment":184},{"nctId":"NCT01290731","phase":"PHASE3","title":"A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":49},{"nctId":"NCT00987337","phase":"PHASE2","title":"Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Hepatitis, Hepatitis C","enrollment":288},{"nctId":"NCT01332955","phase":"PHASE2","title":"Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-04","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":70},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT00056862","phase":"PHASE4","title":"Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-03","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT01172392","phase":"PHASE3","title":"A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-01","conditions":"Chronic Hepatitis B, AgHbs Negativation","enrollment":185},{"nctId":"NCT01056172","phase":"PHASE4","title":"PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)","status":"UNKNOWN","sponsor":"Pusan National University Yangsan Hospital","startDate":"2010-01","conditions":"Chronic Hepatitis C","enrollment":164},{"nctId":"NCT01006031","phase":"PHASE2, PHASE3","title":"Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2009-10","conditions":"Liver Cirrhosis, Hepatitis C Virus, HIV Infection","enrollment":25},{"nctId":"NCT00553930","phase":"PHASE4","title":"Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2007-11","conditions":"Hepatitis C, Chronic, HIV Infections","enrollment":71},{"nctId":"NCT00221286","phase":"PHASE3","title":"Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients","status":"TERMINATED","sponsor":"University Hospital, Bonn","startDate":"2004-09","conditions":"Chronic Hepatitis B, HIV Infections","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HEPATIC ENCEPHALOPATHY"},{"count":1,"reaction":"HYPERGLYCAEMIA"},{"count":1,"reaction":"JAUNDICE"},{"count":1,"reaction":"PANCYTOPENIA"}],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys","peginterferon alfa-2a, Pegasys®"],"phase":"marketed","status":"active","brandName":"PegIFN alfa-2a","genericName":"PegIFN alfa-2a","companyName":"The Second Affiliated Hospital of Chongqing Medical University","companyId":"the-second-affiliated-hospital-of-chongqing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PegIFN alfa-2a is a pegylated interferon alpha-2a that activates innate immune responses by binding to interferon-alpha receptors on immune cells. Used for Chronic hepatitis C, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}